Winchester MD Appoints Head of Marketing

LONDON 19 September 2019 – WINCHESTER MD LIMITED (“Winchester” or the “Company”) is pleased to announce that it has appointed Farrukh Saleem as Head of Marketing with immediate effect.

Farrukh has over 25 years’ experience in sales and marketing within both pharmaceutical and cannabis sectors.

He has in depth experience of the cannabis market, having been a key member of the Bayer team that introduced Sativex (the only licensed non-synthetic cannabis medicine in the UK) in Europe. Prior to joining Winchester MD, Farrukh was Head of Business Development at Spectrum Bio-Medical (a JV between Beckley Canopy Therapeutics and Canopy Growth) advising them on how to launch products in the UK and leading the team that organised the first medical cannabis advisory board in the UK with a number of key opinion leaders participating.

Farrukh has been instrumental in the commercialisation of a number of products and brands across the UK, Europe and EMEA regions, taking several from launch through to multi-million pound annual revenues.

Faz Moshfeghi, CEO of Winchester MD commented: “We are delighted that Farrukh has joined
the Winchester MD management team. Having worked for major multi-national companies as well as early stage businesses, Farrukh brings with him expert knowledge of the industry that will prove to be invaluable as we prepare to launch our first range of products (CBDrive, The Goods and EQL)”.

For more information, contact:
Faz Moshfeghi
CEO
Info@winchestermd.com

About Winchester MD Limited
Winchester MD is a vertically integrated European cannabis company based out of London, UK. The Company was founded in 2018 with an initial focus on CBD Wellness through a revenue producing online retail superstore platform HempElf www.hempelf.com. The Company offers a variety of CBD branded products through its on line superstore and continues to develop and market new products in the CBD Wellness category. In 2019 the Company has expanded into other verticals in the cannabis sector with the vision of becoming a global cannabis leader with cultivation, extraction, CBD wellness and research and development.

This release has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Therefore this release has not been subject to the procedures and controls which would apply if they were made or approved as a financial promotion by an authorised person. This release is not intended to be a financial promotion or offer to the public and the Company is not making an invitation to invest into the share capital of the Company.

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.

The Regulation Services Provider accepts no responsibility for the adequacy or accuracy of this release.

Winchester MD: CEO update for Spanish cultivation

LONDON, UK 16 September 2019 – WINCHESTER MD LIMITED (“Winchester” or the “Company”) is pleased to provide an update on its hemp cultivation operation in Spain.

The Company, with its JV partner, has planted 230,000 hemp plants in June at its 20 Hectare cultivation facility using high-quality EU certified seeds. Since this time Winchester has successfully:

  • Recruited and trained a 50 strong local workforce
  • Implemented a bespoke irrigation system to support the cultivation
  • Constructed and commissioned a dedicated 7000 sq ft drying facility with the capacity to process 100,000KG of dried biomass within three weeks and which is adaptable to serve as an indoor grow facility in the future.

The Company expects to harvest approximately 100,000 KG’s of dried biomass (“Crop”) in October 2019 and will monetize the Crop through various sales channels including the sale of bulk biomass, extraction and sale of distillate and isolate through wholesale and retail channels, and as an ingredient to the Company’s three brands, The Goods, EQL and CBDrive, expected to launch in Q4 2019. The gross margin for each of these revenue channels varies greatly with the sale of bulk biomass representing the lowest gross margin and the use of distillate and isolate in Company owned brands representing the largest gross margin.

Faz Moshfeghi, CEO of Winchester MD commented:

“Against considerable odds the Winchester cultivation team led by Simone Cerri have overcome all obstacles to produce a healthy and thriving crop and beaten all expectations to complete the dry facility in readiness for the imminent harvest of our first crop, that will be later used as our first indoor cultivation centre. This project has been acknowledged by local authorities to be the largest single successful hemp cultivation in the Cadiz region and firmly places Winchester amongst the top cultivators in Spain. We are excited to begin the next chapter of our story as we begin discussions with extraction parties in Poland, Italy and Spain to produce crude  oil, isolate and THC free distillate.”

For more information, contact:
Faz Moshfeghi
CEO

Info@winchestermd.com

About Winchester MD Limited

Winchester MD is a vertically integrated European cannabis company based out of London, UK. The Company was founded in 2018 with an initial focus on CBD Wellness through a revenue-producing online retail superstore platform HempElf www.hempelf.com. The Company offers a variety of CBD branded products through its online superstore and continues to develop and market new products in the CBD Wellness category. In 2019 the Company has expanded into other verticals in the cannabis sector with the vision of becoming a global cannabis leader with cultivation, extraction, CBD wellness and research and development.

Winchester MD Leads Sponsorship of IC3 London

LONDON, 12th July 2019 – WINCHESTER MD LIMITED (“Winchester” or the “Company”) is pleased to announce that it was lead sponsor and an exhibitor at the Inaugural Institutional Capital & Cannabis Conference (Europe) in London.

IC3 forums are a meeting place for investors who wish to learn more about cannabis companies and investment funds who are looking to raise money or showcase their products, and professional service providers who facilitate these groups doing business.

IC3 conferences have earned a reputation in the US for quality content, expert speakers, and a high representation of institutional investors among its delegates. Winchester’s co-founder, Dan Kriznic, and its legal counsel, Fraser McGee both sat on industry expert panels and CEO, Faz Moshfeghi, was interviewed on stage in a strategic session led by Tristan Gervais, the London leader of Canaccord Genuity’s Cannabis sector team.

Faz Moshfeghi, CEO of Winchester MD commented: “We are delighted both with the new contacts we made at IC3 and with the positive feedback from investors and industry stakeholders on our exciting expansion strategy to build on our profitable UK on-line cannabis superstore”.

For more information, please visit www.winchestermd.com

On Behalf of the Board,

Faz Moshfeghi
CEO
Info@winchestermd.com

 About Winchester MD Limited

Winchester MD is a vertically integrated European cannabis company based out of London, UK. The Company was founded in 2018 with an initial focus on CBD Wellness through a revenue producing online retail superstore platform HempElf www.hempelf.com. The Company offers a variety of CBD branded products through its on line superstore and continues to develop and market new products in the CBD Wellness category. In 2019 the Company has expanded into other verticals in the cannabis sector with the vision of becoming a global cannabis leader with cultivation, extraction, CBD wellness and research and development.

Winchester MD Acquires Stake In Harvard Based Synthetic Cannabis Company

LONDON, June 13th, 2019 – WINCHESTER MD LIMITED (“Winchester” or the “Company”) is pleased to announce that it has acquired a minority position in Boston, Massachusetts based private synthetic cannabis company Biotii Technologies Corp.(“Biotii”), created and managed by a group of highly qualified MIT and Harvard health care professionals.

Biotii is actively pursuing genetically engineered microorganisms that express cannabinoid profiles identical to those found in nature – at a fraction of the cost of current cannabis production methods. The scalable synthesizing process will enable the manufacture of lesser-known cannabis compounds, as well as well as tetrahydrocannabinol (THC) and cannabidiol (CBD), at materially lower costs when compared to conventional cultivation and extraction processes.

Traditional cultivation of cannabis plants for the purpose of extracting cannabidiolic acid (CBDA),  including medical THC and CBD is a time, labor and resource intensive endeavor that can result in depressed extraction yields of approximately 2.5%. An alternative tool to produce cannabinoids is biosynthetic engineering, where single cell organisms are programmed to synthesize the enzymes for the metabolic pathway that generates cannabinoids from sugars. Biotii intends to leverage a unique system to mass manufacture large quantities of cannabinoids with a smaller environmental footprint than other known methods.

By 2020, the Biotii team intends to establish processes to mass-produce CBD and medical THC in large quantities (in excess of one hundred metric tons per annum) and boast stable, consistent yields with pharmaceutical grade purities, with the lowest production costs in the industry.

Biotii has in recent times significantly advanced its business plans to include the announced investment on 4th April 2019 from ICC International Cannabis Corp. ((CSE: WRLD.U)(FWB: 8K51)(OTC: WLDCF) (“ICC”) and the subsequent entry into a design and automation agreement (the “Agreement”) with Y Combinator backed Opentrons Labworks Inc. alongside ICC. The Companies will collaborate to architect and construct Canada’s first privately owned high-throughput Bioworks Foundry. The Bioworks Foundry will function as a staging ground for Biotii’s cannabinoid researchers and organism designers to manufacture and analyze prototype enzyme pathways. The state-of-the-art facility will afford International Cannabis and Biotii the ability to scale its synthesized cannabinoid testing processes in a rapid and cost effective fashion. The announcement details can be found in full at: https://intlcannabiscorp.com/news/icc-biotii-y-combinator-backed-biotech-innovator-to-build-bioworks-foundry/

Dr Harrold, CEO, is an MIT instructor with expertise in end-to-end bio-lab management. He is also an entrepreneur having started four start-ups, including two funded by the National Science Foundation. Similarly, Biotii’s chief product officer Sisi Ni is an MIT trained materials scientist and engineer who was previously named as one of Forbes’ 30 under 30’s. Biotii has formed key relationships with leading medical research institutions in both the US and China.

“Biotii has a team of professionals from Harvard and MIT who are looking to disrupt the cannabis space by creating cannabinoids from glucose. This technology would significantly reduce the cost of input for our products which ultimately will bring increased shareholder value” said Faz Moshfeghi, CEO and Co-Founder of Winchester.

For more information, please visit www.winchestermd.com

On Behalf of the Board,
Faz Moshfeghi
CEO
Info@winchestermd.com

About Winchester MD Limited

Winchester MD is a vertically integrated European cannabis company based out of London, UK. The Company was founded in 2018 with an initial focus on CBD Wellness through a revenue producing online retail superstore platform HempElf www.hempelf.com. The Company offers a variety of CBD branded products through its on line superstore and continues to develop and market new products in the CBD Wellness category. In 2019 the Company has expanded into other verticals in the cannabis sector with the vision of becoming a global cannabis leader with cultivation, extraction, CBD wellness and research and development.

This release has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Therefore this release has not been subject to the procedures and controls which would apply if they were made or approved as a financial promotion by an authorised person. This release is not intended to be a financial promotion or offer to the public and the Company is not making an invitation to invest into the share capital of the Company.

 Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.

Announcement Of Chief Financial Officer Appointment

LONDON, 03rd June 2019 –WINCHESTER MD LIMITED (“Winchester” or the “Company”) is pleased to announce that on 28thMay 2019 the Company appointed Ewan Phillips as the Chief Financial Officer of the Company.

Ewan started his career at Deloitte focusing initially on audit and subsequently corporate finance. After Deloitte he spent 17 years on the Board of Deltex Medical Group plc (LON:DEMG) – an innovative UK Life Sciences company, where, as CFO, he led the company to an IPO on AIM gaining valuable exposure to raising capital, investor relations, corporate governance and scaling the business from 15 to over 100 employees and 20x sales growth. Ewan has completed over 50 financing transactions raising over £250 million and over 50 M&A transactions with an aggregate value in excess of £1 billion. He is a Chartered Accountant.

Faz Moshfeghi, CEO and Co-founder of the Company added: “As the business of the Company continues to grow and gather momentum the management made the recent decision to find and bring on board a relevant and successful accounting professional as our CFO. In Ewan we have secured a very experienced and important member of the team to assist with our aggressive acquisition and markets strategy. He will be a valuable member of the team that adds to and complements the talents of the existing management structure that will further enable us.”

For more information, please visitwww.winchestermd.com

On Behalf of the Board,
Faz Moshfeghi
CEO
Info@winchestermd.com

 About Winchester MD Limited

Winchester MD is a vertically integrated European cannabis company based out of London, UK. The Company was founded in 2018 with an initial focus on CBD Wellness through a revenue producing online retail superstore platform HempElf www.hempelf.com. The Company offers a variety of CBD branded products through its on line superstore and continues to develop and market new products in the CBD Wellness category. In 2019 the Company has expanded into other verticals in the cannabis sector with the vision of becoming a global cannabis leader with cultivation, extraction, CBD wellness and research and development.

Update from Project Ronda

LONDON, UK, 28 May 2019 – WINCHESTER MD LIMITED (“Winchester” or the “Company”) is pleased to announce that the cultivation JV in Ronda is well under way with the following key updates:

We have signed agreement with a local greenhouse that specialize in germination of plants so that all the seeds for Ronda are first germinated in small trays and then planted on the land.

250,000 certified seeds have been delivered to the greenhouse to be germinated in batches of 25,000, starting 28 May 2019.

Upgrade to the irrigation system on the property is well underway and on track to complete by 10 June.

Land clearance has been accelerated by the utilization of two tractors and an excavation machine working 7 days a week.

An additional well is being commissioned next week to ensure we have sufficient water during the hot summer months.

For more information, please visit www.winchestermd.com
On Behalf of the Board,
Faz Moshfeghi

CEO
Info@winchestermd.com
About Winchester MD Limited

Winchester MD is a vertically integrated European cannabis company based out of London, UK. The Company was founded in 2018 with an initial focus on CBD Wellness through a revenue producing online retail superstore platform HempElf www.hempelf.com. The Company offers a variety of CBD branded products through its on line superstore and continues to develop and market new products in the CBD Wellness category. In 2019 the Company has expanded into other verticals in the cannabis sector with the vision of becoming a global cannabis leader with cultivation, extraction, CBD wellness and research and development.

This release has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Therefore this release has not been subject to the procedures and controls which would apply if they were made or approved as a financial promotion by an authorised person. This release is not intended to be a financial promotion or offer to the public and the Company is not making an invitation to invest into the share capital of the Company.

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.

The Regulation Services Provider accepts no responsibility for the adequacy or accuracy of this release.

Winchester MD Appoints Chief Legal Officer And Regulatory Affairs

LONDON, UK, 13 May 2019 – WINCHESTER MD LIMITED (“Winchester” or the “Company”) is pleased to announce that on 09 May 2019 the Company appointed Fraser McGee (“McGee”) as Chief Legal Officer and Regulatory Affairs at its head office in London.

McGee is a UK qualified solicitor who has specialised in corporate finance and investment fund work with prominent law firms in the UK before moving to work in in-house with investment banks. He was also admitted as a solicitor of the Eastern Caribbean Supreme Court and has worked for a BVI and Cayman Islands offshore law firm.

McGee previously worked as general counsel in the Special Situations team, Energy and Technology Fund, at the globally focused hedge fund RAB Capital plc. McGee was also the CEO of an AIM quoted natural resources business before setting up an independent consultancy company to provide general counsel services to the alternative investment sector. That work extended to the European medical cannabis space from the early part of 2018 and included working with networks of entrepreneurs, professional service providers and investors in the industry around the world.

“The global cannabis industry is highly regulated with varying laws by Country. We recognized the need to bring on a Chief Legal Officer and Regulatory Affairs position early in our growth plan to ensure we are on top of the cannabis regulations as they change. This gives the Company the edge in the industry in order to quickly adapt to conform with regulation and monetize a return for our shareholders. McGee is one of the very few city professionals who have actual experience in the Cannabis industry. He brings to the Company a breadth of legal experience in private equity and investment banking which fits well with our fundraising strategy. In addition, we are moving at a rapid speed to grow Winchester not only organically but also by way of acquisition. McGee will be an integral part of our aggressive acquisition strategy.” Explains Faz Moshfeghi, CEO of Winchester.

For more information, please visit www.winchestermd.com
On Behalf of the Board,
Faz Moshfeghi

CEO
Info@winchestermd.com
About Winchester MD Limited

Winchester MD is a vertically integrated European cannabis company based out of London, UK. The Company was founded in 2018 with an initial focus on CBD Wellness through a revenue producing online retail superstore platform HempElf www.hempelf.com. The Company offers a variety of CBD branded products through its on line superstore and continues to develop and market new products in the CBD Wellness category. In 2019 the Company has expanded into other verticals in the cannabis sector with the vision of becoming a global cannabis leader with cultivation, extraction, CBD wellness and research and development.

This release has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Therefore this release has not been subject to the procedures and controls which would apply if they were made or approved as a financial promotion by an authorised person. This release is not intended to be a financial promotion or offer to the public and the Company is not making an invitation to invest into the share capital of the Company.

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.

The Regulation Services Provider accepts no responsibility for the adequacy or accuracy of this release.

Winchester MD Signs JV to Cultivate Industrial Hemp in Ronda, Spain and Acquires 1.6 Million EU Registered Seeds

LONDON, UK, May 9, 2019 – WINCHESTER MD LIMITED (“Winchester” or the “Company”) is pleased to announce that on April 30, 2019, the Company signed a joint venture agreement (“JV”)  with a land owner in Ronda, Spain for the purpose of cultivating industrial hemp (“Cultivation Property”). In addition, the Company has purchased 1.6 million European Union registered hemp seeds for 2019 hemp cultivation on the Cultivation Property as well as for sale on the retail CBD superstore operated by Winchester MD (www.hempelf.com). The Company’s agreement with the land owner is to invest in all farming costs including but not limited to seeds, labour, irrigation, and cultivation in exchange for 80% of the economics from the JV.

Faz Moshfeghi, CEO of Winchester MD, commented, “The cultivation plot comprises of 20 hectares of irrigated farming land currently growing oats in the south of Spain. We have started to revamp the irrigation system to supply water across the land from the existing underground freshwater wells situated on the property. Our seeds will be germinated indoors using a nearby greenhouse to ensure a high germination rate. We expect to have the seedlings in the ground within the next 3 weeks and have engaged a local labour agency who will manage the hiring and payroll of our workforce for the project. This is the first biomass crop for Winchester and we are already having discussions with a European extraction partners in order to extract our biomass and produce CBD Isolate, which is expected by October 2019. Based on historic data for the performance of the EU-registered seeds and the experience of our farmers, we anticipate cultivating approximately 100,000 kilograms of hemp biomass in 2019 from the Cultivation Property. We are also expecting to extract 3,000 to 4,000 kilograms of CBD isolate, which at the current average price per kilogram, would yield gross sales in the range of €18 million to €24 million.”

For more information, please visit www.winchestermd.com

On Behalf of the Board,
Farzad Moshfeghi
CEO
Info@winchestermd.com
About Winchester MD Limited

Winchester MD is a vertically integrated, European cannabis company based in London, UK. The Company was founded in 2018 with an initial focus on CBD Wellness through a revenue-producing, online retail superstore platform Hemp Elf www.hempelf.com. The Company offers a variety of CBD branded products through its online superstore and continues to develop and market new products in the CBD Wellness category. In 2019, the Company has expanded into other verticals in the cannabis sector with the vision of becoming a global cannabis leader with cultivation, extraction, CBD Wellness, and research and development.

This release has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Therefore this release has not been subject to the procedures and controls which would apply if they were made or approved as a financial promotion by an authorised person. This release is not intended to be a financial promotion or offer to the public and the Company is not making an invitation to invest into the share capital of the Company.

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.

The Regulation Services Provider accepts no responsibility for the adequacy or accuracy of this release.

Winchester Attends First Wednesdays – The European Cannabis Professional Network

LONDON, UK, May 2, 2019 –WINCHESTER MD LIMITED (“Winchester” or the “Company”) attended the First Wednesday Cannabis Professional Network event on May 1, 2019  in London, UK sponsored by Canaccord and DAC Beachcroft. First Wednesdays is powered by Hanway Associates, London’s global cannabis consultancy –your knowledge & network partner.London hosts include Canaccord Genuity Limited’s Head of European Cannabis Investment banking team, Tristan Gervais, as well as other.

“The evening is brimming with a slightly breathless, nothing-can-stop-us zeal – a brand of enthusiasm I recognise from the years I spent in California covering Silicon Valley for this magazine.”– Rhys Blakely, The Times

Faz, CEO of Winchester, commented “This is a great event for entrepreneurs and is held on the first Wednesday of every month. The cannabis industry in Europe has been evolving at a rapid speed and events like this bring like minded people together to discuss challenges and opportunities facing all of us in the global legalization of Cannabis. Our team at Winchester strives to continuously adapt our business model with the changes in legalization while maintaining quality products for our customers who order through our on-line CBD Wellness retail platform www.hempelf.com.”

In attendance at the event were Faz Moshfeghi, CEO Winchester Corporate, Marti Moshfeghi, CEO Winchester CBD Wellness, Dan Kriznic VP Public Markets and Business Development and Mike Kriznic, Italy Country manager.

For more information, please visit www.winchestermd.com

On Behalf of the Board,
Faz Moshfeghi
CEO
Info@winchester-md.com

About Winchester MD Limited

Winchester is a vertically integrated European cannabis company based out of London, UK. The Company was founded in 2018 with an initial focus on CBD Wellness through a revenue producing online retail platform Hemp Elf www.hempelf.com. The Company offers a variety of CBD products through its on line store and continues to develop and market new products in the CBD Wellness category. In 2019 the Company has expanded into other verticals in the cannabis sector including with the vision of becoming a global cannabis leader with cultivation, extraction, CBD wellness, R&D and clinics/education.

This release has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Therefore this release has not been subject to the procedures and controls which would apply if they were made or approved as a financial promotion by an authorised person. This release is not intended to be a financial promotion or offer to the public and the Company is not making an invitation to invest into the share capital of the Company.

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.

The Regulation Services Provider accepts no responsibility for the adequacy or accuracy of this release.

Winchester MD Launches Winchester MD and Hemp Elf CBD Retail Website Redesign

LondonApr. 30, 2019 – WINCHESTER MD LIMITED (“Winchester”or the “Company”) is pleased to announce that the Company launched its initial website for Winchester at www.winchestermd.com as well as a full redesign of the Company’s Hemp Elf on-line CBD Wellness site at www.hempelf.com.

Faz Moshfeghi, CEO of Winchester MD, comments on the history and background of Winchester “15 months ago HempElf was created (www.hempelf.com) out of the idea to bring professionalism and quality to the cannabis industry in the UK and through-out Europe. My son Marti approached me with the idea of procuring and fulfilling CBD products in the UK market. I initially had my doubts about cannabis – like most people in UK – but because of Marti’s passion and after extensive research I decided to support my son and we teamed up to launch HempElf.  What we learnt early on in our journey was that many CBD businesses were in a rush to make products without really paying any attention to the aesthetics, looks and taste of their products. They were focused on quoting large CBD percentages and claim that because their product had CBD, it was justifiable to have a strong bitter taste. We realised from the outset that quality and reliability should be major considerations when selecting products and we set about sampling as many products available on the market as possible and by Feb 2018 we had selected our initial range of products. HempElf was launched as an online store, operated by Winchester MD Limited (formerly Green Biosciences) and offering 15 products. 12 months later we have over 100 products for sale in our online store with monthly sales in excess of 25,000 orders and 45,000 online visitors per month. We have been voted as UK’s No 1 supplier of quality CBD flowers by two of the industry publication CBDTesters and High&Polite and have built a customer base of more than 10,000 loyal followers. Throughout this time we have remained true to our founding principles of Quality, Reliability and Transparency and our trading name HempElf.com has become synonymous with high quality products. Winchester is one of the first CBD companies in the UK to successfully put in place credit card handling facilities and simplify the customer shopping experience. In February 2019 we secured a strategic partnership with High Standard Capital from Vancouver, operated by Dan Kriznic – former CEO of Invictus MD (TSXV:GENE) (one of Canada’s early entrants into the legal cannabis space) and a pioneer in the cannabis space owning and operating cannabis assets in Canada, United States, Jamaica, Peru, Mexico and now Europe. We continue to look for new products for HempElf based on customer demand and also plan on introducing our own branded products.”

On Behalf of the Board,
Farzad Moshfeghi
CEO
info@winchestermd.com

About Winchester MD Limited

Winchester is a vertically integrated European cannabis company based out of London, UK. The Company was founded in 2018 with an initial focus on CBD Wellness through a revenue producing online retail platform Hemp Elf www.hempelf.com. The Company offers a variety of CBD products through its on line store and continues to develop and market new products in the CBD Wellness category. In 2019 the Company has expanded into other verticals in the cannabis sector including with the vision of becoming a global cannabis leader with cultivation, extraction, CBD wellness, R&D and clinics/education.

This release has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Therefore this release has not been subject to the procedures and controls which would apply if they were made or approved as a financial promotion by an authorised person. This release is not intended to be a financial promotion or offer to the public and the Company is not making an invitation to invest into the share capital of the Company.

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.

The Regulation Services Provider accepts no responsibility for the adequacy or accuracy of this release.